SPOTLIGHT -
Allergan's brimonidine tartrate (Alphagan) will have new labeling that indicates its 0.5% strength is suitable for pediatric patients over 2 years old.
Keratoconus in a pediatric population has higher prevalence than expected
ROP: Treating and preventing blindness in preterm babies
Partners collaborate on integration of AI-supported ROP telemedicine globally
Managing a changing landscape of IRD pediatric cases
An approach to preventing progression of pediatric myopia
AAO 2023: Phase III CHAMP and more trials pioneering myopia management in children